Pfizer Inc. $PFE Shares Purchased by CVA Family Office LLC

CVA Family Office LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 141.6% in the 2nd quarter, Holdings Channel reports. The fund owned 12,502 shares of the biopharmaceutical company’s stock after acquiring an additional 7,327 shares during the quarter. CVA Family Office LLC’s holdings in Pfizer were worth $303,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. GKV Capital Management Co. Inc. acquired a new position in Pfizer in the 1st quarter valued at $27,000. Curio Wealth LLC boosted its holdings in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,098 shares in the last quarter. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter worth about $28,000. North Capital Inc. purchased a new position in Pfizer during the first quarter worth about $28,000. Finally, Harbor Asset Planning Inc. acquired a new stake in Pfizer in the second quarter valued at about $29,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.5%

Pfizer stock opened at $24.79 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market capitalization of $140.92 billion, a price-to-earnings ratio of 13.18, a price-to-earnings-growth ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $29.17. The stock’s fifty day moving average is $24.87 and its two-hundred day moving average is $24.18.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. The ex-dividend date of this dividend is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is 91.49%.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Bank of America boosted their target price on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Morgan Stanley dropped their price objective on Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a report on Friday, October 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Saturday. Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.